TMBR
Income statement / Annual
Last year (2022), Timber Pharmaceuticals, Inc.'s total revenue was $83,177.00,
a decrease of 71.87% from the previous year.
In 2022, Timber Pharmaceuticals, Inc.'s net income was -$19.38 M.
See Timber Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
01/31/2020 |
01/31/2019 |
01/31/2018 |
01/31/2017 |
01/31/2016 |
12/31/2014 |
09/30/2013 |
| Operating Revenue |
$83,177.00
|
$295,738.00
|
$453,810.00
|
$324,646.00
|
$57,000.00
|
$73,000.00
|
$100,000.00
|
$64,000.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$13.30 M |
$6.15 M |
$1.50 M |
$3.38 M |
$83,000.00 |
$250,000.00 |
$516,000.00 |
$237,000.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$13.22 M |
-$5.85 M |
-$1.05 M |
-$3.06 M |
-$26,000.00 |
-$177,000.00 |
-$416,000.00 |
-$173,000.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
-158.92 |
-19.79 |
-2.31 |
-9.42 |
-0.46 |
-2.42 |
-4.16 |
-2.7 |
0 |
0 |
| Research and Development
Expenses |
$13.30 M
|
$6.15 M
|
$15.10 M
|
$3.38 M
|
$9.08 M
|
$9.14 M
|
$10.16 M
|
$5.70 M
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.24 M
|
$5.14 M
|
$4.65 M
|
$4.17 M
|
$0.00
|
$52,305.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.16 M
|
$2.42 M
|
$3.20 M
|
$5.11 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$6.02 M
|
$5.39 M
|
$4.06 M
|
$586,559.00
|
$7.40 M
|
$7.56 M
|
$7.85 M
|
$9.28 M
|
$0.00
|
$52,305.00
|
| Other Expenses |
-$83,177.00 |
-$590,794.00 |
-$453,810.00 |
$0.00 |
$0.00 |
$0.00 |
-$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$19.24 M |
$10.95 M |
$18.71 M |
$586,715.00 |
$16.48 M |
$16.70 M |
$18.01 M |
$14.99 M |
$0.00 |
$52,305.00 |
| Cost And Expenses |
$19.24 M |
$10.95 M |
$18.71 M |
$3.97 M |
$16.56 M |
$16.95 M |
$18.53 M |
$15.22 M |
$0.00 |
$52,305.00 |
| Interest Income |
$2,445.00 |
$15,551.00 |
$816,657.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$1.00 |
| Interest Expense |
$228,456.00 |
$15,551.00 |
$4.42 M |
$0.00 |
$28,000.00 |
$364,000.00 |
$163,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$77,445.00
|
$272,882.00
|
$2.43 M
|
$171,860.00
|
$62,000.00
|
$52,000.00
|
$260,000.00
|
$86,000.00
|
$0.00
|
$0.00
|
| EBITDA |
-$19.16 M
|
-$10.38 M
|
-$17.78 M
|
-$45,558.00
|
-$17.17 M
|
-$16.88 M
|
-$17.98 M
|
-$15.16 M
|
$0.00
|
-$52,305.00
|
| EBITDA Ratio |
-230.33 |
-36.01 |
-39.17 |
-0.14 |
-301.16 |
-327.18 |
-179.81 |
-242.31 |
0 |
0 |
| Operating Income Ratio
|
-231.26
|
-36.01
|
-44.54
|
-11.23
|
-302.25
|
-327.89
|
-182.41
|
-243.66
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$136,454.00
|
-$19,170.00
|
$5.13 M
|
-$156.00
|
-$750,000.00
|
$238,000.00
|
-$163,000.00
|
-$436,000.00
|
$0.00
|
$1.00
|
| Income Before Tax |
-$19.37 M |
-$10.67 M |
-$15.08 M |
-$3.64 M |
-$17.26 M |
-$16.64 M |
-$18.40 M |
-$15.59 M |
$0.00 |
-$52,304.00 |
| Income Before Tax Ratio
|
-232.9
|
-36.08
|
-33.23
|
-11.23
|
-302.74
|
-227.92
|
-184.04
|
-243.66
|
0
|
0
|
| Income Tax Expense |
$7,600.00 |
-$30,242.00 |
$37,842.00 |
-$156.00 |
$2,000.00 |
-$7.66 M |
$2,000.00 |
$4,000.00 |
$0.00 |
$0.00 |
| Net Income |
-$19.38 M |
-$10.64 M |
-$15.12 M |
-$3.69 M |
-$17.26 M |
-$8.98 M |
-$18.41 M |
-$15.60 M |
$0.00 |
-$52,304.00 |
| Net Income Ratio |
-232.99 |
-35.97 |
-33.31 |
-11.37 |
-302.77 |
-122.99 |
-184.06 |
-243.72 |
0 |
0 |
| EPS |
-9.19 |
-13.15 |
-48.15 |
-29.31 |
-1340.11 |
-1567.94 |
-7710.93 |
-13030.91 |
0 |
-0.0058 |
| EPS Diluted |
-9.19 |
-13.15 |
-48.15 |
-29.31 |
-1340.11 |
-1567.94 |
-7710.93 |
-13030.91 |
0 |
-0.0058 |
| Weighted Average Shares
Out |
$2.11 M
|
$808,811.00
|
$313,997.00
|
$125,914.00
|
$12,878.00
|
$5,726.00
|
$2,387.00
|
$1,197.00
|
$204,340.00
|
$9.00 M
|
| Weighted Average Shares
Out Diluted |
$2.11 M
|
$808,811.00
|
$313,997.00
|
$125,914.00
|
$12,878.00
|
$5,726.00
|
$2,387.00
|
$1,197.00
|
$204,340.00
|
$9.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
